MSD acquires Harpoon for $680m to strengthen T-cell engager armoury

Set to lose Keytuda patent protection in 2028, MSD is shoring up its oncology portfolio with immunotherapies.

Jan 9, 2024 - 18:00

MSD acquires Harpoon for $680m to strengthen T-cell engager armoury

Set to lose Keytuda patent protection in 2028, MSD is shoring up its oncology portfolio with immunotherapies.

Read the original article

Tags:

Previous Article

Zealand raises DKr1.45bn to advance obesity pipeline

Biocytogen and Radiance partner for bispecific antibody-drug conjugate

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Related Posts

Gates Foundation to fund trial of long-awaited new tuberculosis vaccine candidate

Gates Foundation to fund trial of long-awaited new tube...

Jun 28, 2023

FDA grants fast track status to Innovent’s IBI363 for melanoma

FDA grants fast track status to Innovent’s IBI363 for m...

Sep 4, 2024

Eli Lilly reiterates POINT acquisition plans with tender offer extension

Eli Lilly reiterates POINT acquisition plans with tende...

Nov 12, 2023